Department of Otolaryngology-Head and Neck Surgery, Shuang Ho Hospital, Taipei Medical University, Taiwan.
Department of Oral and Maxillofacial Surgery, Wan Fang Hospital, Taipei Medical University, Taiwan.
Radiother Oncol. 2018 Oct;129(1):23-29. doi: 10.1016/j.radonc.2017.12.004. Epub 2017 Dec 22.
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent low-dose (LD) or high-dose (HD) cisplatin with radiotherapy on nasopharyngeal cancer (NPC). Thus, we conducted a propensity-score-matched, nationwide, population-based cohort study in Taiwan to investigate the outcomes of LD-concurrent chemoradiotherapy (CCRT) or HD-CCRT with intensity-modulated radiotherapy (IMRT) in patients with advanced NPC.
In this study, patients were categorized into 2 groups according to their chemotherapy regimen: HD-CCRT and LD-CCRT groups.
We enrolled 1968 patients (328 and 1640 in the LD-CCRT and HD-CCRT groups, respectively) who had received CCRT with IMRT. According to both univariate and multivariate Cox regression analyses, a hazard ratio (95% confidence interval) of 0.75 (0.54-1.06, P = .103) was derived for the HD-CCRT group.
LD-CCRT or HD-CCRT with IMRT can be a standard treatment that can prolong the survival of patients with advanced NPC.
没有大规模、头对头、III 期、随机、对照试验,样本量充足,研究了低剂量(LD)或高剂量(HD)顺铂与放疗联合治疗鼻咽癌(NPC)的效果。因此,我们在台湾进行了一项倾向评分匹配的全国性基于人群的队列研究,以调查高强度调强放疗(IMRT)中 LD 同期放化疗(CCRT)或 HD-CCRT 对晚期 NPC 患者的疗效。
在这项研究中,根据化疗方案将患者分为两组:HD-CCRT 组和 LD-CCRT 组。
我们共纳入了 1968 名患者(LD-CCRT 组和 HD-CCRT 组分别为 328 名和 1640 名),他们均接受了 IMRT 下的 CCRT。根据单因素和多因素 Cox 回归分析,HD-CCRT 组的风险比(95%置信区间)为 0.75(0.54-1.06,P=0.103)。
IMRT 下的 LD-CCRT 或 HD-CCRT 可以作为一种标准治疗方法,延长晚期 NPC 患者的生存时间。